Список литературы

Поставить закладку

Jennette J.C., Falk R.J., Bacon P.A., et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides // Arthritis Rheum. – 2013. – Vol. 65. – № 1. – P.1–11.
Lyons P.A., Rayner T.F., Triveldi S., et al. Genetically Distinct Subsets within ANCA- Associated Vasculitis // N. Engl. J. Med. – 2012. – Vol. 367. – № 3. – P.214–223.
Xie G., Roshandel D., Sherva R., et al. Association of granulomatosis with polyangiitis (Wegener’s) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis // Arthritis. Rheum. – 2013. – Vol. 65. – № 9. – P.2457–2468.
Tadema H., Abdulahad W.H., Lepse N., et al. Bacterial DNA motifs trigger ANCA production in ANCA-associated vasculitis in remission // Rheumatology (Oxford). – 2011. – Vol. 50. – № 4. – P.689–696.
Bienaimé F., Clerbaux G., Plaisier E., et al. D-Penicillamine-Induced ANCA-Associated Crescentic Glomerulonephritis in Wilson Disease // Am. J. Kidney Dis. – 2007. – Vol. 50. – № 5. – P.821–825.
Nolan A.L., Jen K.Y. Pathologic manifestations of levamisole-adulterated cocaine exposure // Diagnostic Pathology. – 2015. – Vol. 10. – P.48.
Gómez-Puerta J.A., Gedmintas L., Costenbader K.H. The association between silica exposure and development of ANCA-associated vasculitis: systematic review and meta-analysis // Autoimmun. Rev. – 2013. – Vol. 12. – № 12. – P.1129–1135.
Xiao H., Heeringa P., Hu P., et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice // J. Clin. Invest. – 2002. – Vol. 110. – № 7. – P.955–963.
Little M.A., Al-Ani B., Ren S., et al. Anti-proteinase 3 anti-neutrophil cytoplasm autoantibodies recapitulate systemic vasculitis in mice with a humanized immune system // PLoS One. – 2012. – Vol. 7. – № 1. – P.e28626.
Schlieben D.J., Korbet S.M., Kimura R.E., et al. Pulmonary-renal syndrome in a newborn with placental transmission of ANCAs // Am. J. Kidney Dis. – 2005. – Vol. 45. – № 4. – P.758– 761.
Kemna M.J., Damoiseaux J., Austen J., et al. ANCA as a predictor of relapse: Useful in patients with renal involvement but not in patients with nonrenal disease // J. Am. Soc. Nephrol. – 2015. – Vol. 26. – № 3. – P.537–542.
Muller Kobold A.C., van der Geld Y.M., Limburg P.C., et al. Pathophysiology of ANCA- associated glomerulonephritis // Nephrol. Dial. Transplant. – 1999. – Vol. 14. – № 6. – P.1366– 1375.
Falk R.J., Terrell R.S., Charles L.A., et al. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro // Proc. Natl. Acad. Sci. U. S. A. – 1990. – Vol. 87. – № 11. – P.4115–4119.
Radford D.J., Luu N.T., Hewins P., et al. Antineutrophil cytoplasmic antibodies stabilize adhesion and promote migration of flowing neutrophils on endothelial cells // Arthritis Rheum. – 2001. – Vol. 44. – № 12. – P.2851–2861.
Kessenbrock K., Krumbholz M., Schönermarck U., et al. Netting neutrophils in autoimmune small-vessel vasculitis // Nat. Med. – 2009. – Vol. 15. – № 6. – P.623–625.
Hilhorst M., van Paassen P., van Rie H., et al. Complement in ANCA-associated glomerulonephritis // Nephrol. Dial. Transpl. – 2015. – Vol. 32. – № 8. – P.1302–1313.
Gou S.J., Yuan J., Chen M., et al. Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis // Kidney Int. – 2013. – Vol. 83. – № 1. – P.129–137.
Gou S.J., Yuan J., Wang C., et al. Alternative complement pathway activation products in urine and kidneys of patients with ANCA-associated GN // Clin. J. Am. Soc. Nephrol. – 2013. – Vol. 8. – № 11. – P.1884–1891.
Jayne D.R.W., Bruchfeld A.N., Harper L., et al. Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis // J. Am. Soc. Nephrol. – 2017. – Vol. 28. – № 9. – P.2756–2767.
Hruskova Z., Rihova Z., Mareckova H., et al. Intracellular cytokine production in ANCA- associated vasculitis: low levels of interleukin-10 in remission are associated with a higher relapse rate in the long-term follow-up // Arch. Med. Res. – 2009. – Vol. 40. – № 4. – P.276– 284.
Lamprecht P., Wieczorek S., Epplen J.T., et al. Granuloma formation in ANCA- associated vasculitides // A.P.M.I.S. Suppl. – 2009. – № 127. – P.32–36.
Watts R.A., Mahr A., Mohammad A.J., et al. Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis // Nephrol. Dial. Transplant. – 2015. – Vol. 30. – Suppl. 1. – P.i14-22.
Berti A., Gall E.C., Cornec D., et al. Incidence, prevalence, mortality and chronic renal damage of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a 20-year population-based cohort // Nephrol. Dial. Transplant. – 2019. – Vol. 34. – № 9. – P.1508–1517.
Новиков П.И., Моисеев С.В., Кузнецова Е.И., [и др]. Изменение клинического течения и прогноза гранулематоза с полиангиитом (Вегенера): результаты 40-летнего наблюдения / Клиническая фармакология и терапия. – 2014. – Т. 23. – № 1. С.32-37.
Томилина Н.А., Бирюкова Л.С., Фролова Н.Ф., [и др.]. Клинико-морфологическая характеристика и прогноз разных гистоморфологических вариантов быстропрогрессирующего гломерулонефрита, ассоциированного с АНЦА-васкулитом // Нефрология и диализ. – 2017. – Т. 19. – № 4. – С.466–477.
Mohammad A.J., Jacobsson L.T., Westman K.W., et al. Incidence and survival rates in Wegener’s granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa // Rheumatology. – 2009. – Vol. 48. – № 12. – P.1560–1565.
Kallenberg C.G.M. Pathogenesis of ANCA-associated vasculitides // Ann. Rheum. Dis. – 2011. – Vol. 70. – Suppl. 1. – P.i59–i63.
Novikov P., Smitienko I., Bulanov N., et al. Testing for antineutrophil cytoplasmic antibodies (ANCAs) in patients with systemic vasculitides and other diseases // Ann. Rheum. Dis. – 2016. – Vol. 76. – № 8. – P.e23.
Jennette J.C., Wilkman A.S., Falk R.J. Anti-neutrophil cytoplasmic autoantibody- associated glomerulonephritis and vasculitis // Am. J. Pathol. – 1989. – Vol. 135. – № 5. – P.921–930.
Bosch X., Mirapiex E., Font J., et al. Anti-myeloperoxidase autoantibodies in patients with necrotizing glomerular and alveolar capillaritis // Am. J. Kidney Dis. – 1992. – Vol. 20. – № 3. – P.231–239.
Holle J.U., Laudien M., Gross W.L. Clinical Manifestations and Treatment of Wegener’s Granulomatosis // Rheum. Dis. Clin. North. Am. – 2010. – Vol. 36. – № 3. – P. 507–526.
Villiger P.M., Guillevin L. Microscopic polyangiitis: Clinical presentation // Autoimmun. Rev. – 2010. – Vol. 9. – № 12. – P.812–819.
Щеголева Е.М., Буланов Н.М., Новиков П.И., и соавт. Клинические особенности поражения почек при микроскопическом полиангиите // Терапевтический архив. – 2018. Т. 90. – № 6. – С. 55–58.
Guillevin L., Cohen P., Gayraud M., et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients // Medicine (Baltimore). – 1999. – Vol. 78. – № 1. – P.26–37.
Буланов Н.М., Моисеев С.В., Новиков П.И., [и др.]. Поражение почек при различных вариантах АНЦА-ассоциированного васкулита // Клиническая фармакология и терапия. – 2016. – Т. 25. – № 5. – С.23–29.
Leavitt R.Y., Fauci A.S., Bloch D.A., et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis // Arthritis Rheum. – 1990. – Vol. 33. – № 8. – P.1101–1107.
Masi A.T., Hunder G.G., Lie J.T., et al. The American College of Rheumatology 1990 criteria for the classification of Churg‐Strauss syndrome (allergic granulomatosis and angiitis) // Arthritis Rheum. – 1990. – Vol. 33. – № 8. – P.1094–1100.
Seeliger B., Sznajd J., Robson J.C., et al. Are the 1990 American College of Rheumatology vasculitis classification criteria still valid? // Rheumatology (Oxford). – 2017. – Vol. 56. – № 7. – P.1154–1161.
Watts R., Lane S., Hanslik T., et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies // Ann. Rheum. Dis. – 2007. – Vol. 66. – № 2. – P.222–227.
Бекетова Т.В. Алгоритм диагностики системных васкулитов, ассоциированных с антинейтрофильными цитоплазматическими антителами // Терапевтический архив. – 2018. – Т. 90. – № 5. – С.13–21.
Mukhtyar C., Guillevin L., Cid M.C., et al. EULAR recommendations for the management of primary small and medium vessel vasculitis // Ann. Rheum. Dis. – 2009. – Vol. 68. – № 3. – P.310–317.
Jennette J.C. Rapidly progressive crescentic glomerulonephritis // Kidney Int. – 2003. – Vol. 63. – № 3. – P.1164–1177.
Falk R.J., Moore D.T., Hogan S.L., et al. A renal biopsy in essential for the management of ANCA-positive patients with glomerulonephritis // Sarcoidosis Vasc. Diffuse Lung Dis. – 1996. – Vol. 13. – № 3. – P.230–231.44.
Клинические рекомендации. Хроническая болезнь почек. 2020. https://rusnephrology.org/wp-content/uploads/2020/12/CKD_final.pdf
Deshayes S., Aouba A., Khoy K., et al. Hypocomplementemia is associated with worse renal survival in ANCA-positive granulomatosis with polyangiitis and microscopic polyangiitis // PLoS One. – 2018. – Vol. 13. – № 4. –P.e0195680.
Augusto J.F., Langs V., Demiselle J., et al. Low serum complement C3 levels at diagnosis of renal ANCA-associated vasculitis is associated with poor prognosis // PLoS One. – 2016. – Vol. 11. – № 7. – P.e0158871.
Crnogorac M., Horvatic I., Kacinari P., et al. Serum C3 complement levels in ANCA associated vasculitis at diagnosis is a predictor of patient and renal outcome // J. Nephrol. – 2018. – Vol. 31. – № 2. – P.257–262.
Guchelaar N.A.D., Waling M., Adhin A., et al. The value of anti-neutrophil cytoplasmic antibodies (ANCA) testing for the diagnosis of ANCA-associated vasculitis, a systematic review and meta-analysis // Autoimmun. Rev. – 2021. – Vol. 20. – № 1. – P. 102716.
Bossuyt X., Cohen Tervaert J.W., Arimura Y., et al. Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis // Nat. Rev. Rheumatol. – 2017. – Vol. 13. – № 11. – P.683–692.
Damoiseaux J., Csernok E., Rasmussen N., et al. Detection of antineutrophil cytoplasmic antibodies (ANCAs): a multicentre European Vasculitis Study Group (EUVAS) evaluation of the value of indirect immunofluorescence (IIF) versus antigen-specific immunoassays // Ann. Rheum. Dis. – 2017. – Vol. 76. – № 4. – P.647–653.
Savige J., Dimech W., Fritzler M., et al. Addendum to the International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies: Quality Control Guidelines, Comments, and Recommendations for Testing in Other Autoimmune Diseases // Am. J. Clin. Pathol. – 2003. – Vol. 120. – № 3. – P.312–318.
Csernok E., Damoiseaux J., Rasmussen N., et al. Evaluation of automated multi- parametric indirect immunofluorescence assays to detect anti-neutrophil cytoplasmic antibodies (ANCA) in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) // Autoimmun. Rev. – 2016. – Vol. 15. – № 7. – P.736–741.
Hogan P.C.P. et al. Biomarkers Predict Relapse in Granulomatosis with Polyangiitis // J. Biomarkers. Hindawi Limited, 2014. Vol. 2014. P. 1–4.
Wester Trejo M.A.C., Floßmann O., Westman K.W., et al. Renal relapse in antineutrophil cytoplasmic autoantibody-associated vasculitis: unpredictable, but predictive of renal outcome // Rheumatology (Oxford). – 2019. – Vol. 58. – № 1. – P.103–109.
Смирнов А.В., Ватазин А.В., Голубев Р.В. Клинические рекомендации. Острое повреждение почек. 2020. P. 1–142. https://rusnephrology.org/wp- content/uploads/2020/12/AKI_final.pdf
Robson J., Doll H., Suppiah R., et al. Damage in the anca-associated vasculitides: long- term data from the European vasculitis study group (EUVAS) therapeutic trials. // Ann. Rheum. Dis. – 2015. – Vol. 74. – № 1. – P. 177–184.
Hogan S.L., Falk R.J. Chin H., et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. // Ann. Intern. Med. 2005. – Vol. 143. – № 9. – P. 621–631.
Suppiah R., Mukhtyar C., Flossman O., et al. A cross-sectional study of the Birmingham vasculitis activity score version 3 in systemic vasculitis // Rheumatology. – 2011. – Vol. 50. – № 5. – P. 899–905.
Exley A.R., Bacon P.A., Luqmani R.A., et al. Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitides // Arthritis Rheum. – 1997. – Vol. 40. – № 2. – P. 371–380.
Chakravarty K., McDonald H., Pullar T., et al. BSR/BHPR guideline for disease- modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists // Rheumatology. – 2008. – Vol. 47. – № 6. – P. 924–925.
Jayne D., Rasmussen N., Andrassy K., et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies // N. Engl. J. Med. – 2003. – Vol. 349. – № 1. – P.36–44.
Talar-Williams C., Hijazi Y.M., Walther M.M., et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis // Ann. Intern. Med. – 1996. – Vol. 124. – № 5. – P. 477–484.
Knight A., Askling J., Granath F., et al. Urinary bladder cancer in Wegener’s granulomatosis: Risks and relation to cyclophosphamide // Ann. Rheum. Dis. – 2004. – Vol. 63. – № 10. – P.1307–1311.
Stillwell T.J., Benson R.C., DeRemee R.A., et al. Cyclophosphamide‐induced bladder toxicity in Wegener’s granulomatosis // Arthritis Rheum. – 1988. – Vol. 31. – № 4. – P.465–470.
Tomasson G., Grayson P.C., Mahr A.D., et al. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis-a meta-analysis // Rheumatology. – 2012. – Vol. 51. – № 1. – P. 100–109.
Finkielman J.D., Merkel P.A., Schroeder D., et al. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis // Ann. Intern. Med. – 2007. – Vol. 147. – № 9. – P. 611–619.
Boomsma M.M., Stegeman C.A., van der Leij M.J., et al. Prediction of relapses in Wegener’s granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study // Arthritis Rheum. – 2000. – Vol. 43. – № 9. – P. 2025–2033.
Venhoff N., Effelsberg N.M., Salzer U., et al. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA- associated vasculitides // PLoS One. – 2012. – Vol. 7. – № 5. – P.e37626.
Marco H., Smith R.M., Jones R.B., et al. The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease // BMC Musculoskelet. Disord. – 2014. – Vol. 15. – № 1. – P.178.
Feragalli B., Mantini C., Sperandeo M., et al. The lung in systemic vasculitis: Radiological patterns and differential diagnosis // Br. J. Radiol. – 2016. – Vol. 89. – № 1061. – P.20150992.
Huang S., Shen Q., Yang R., et al. An evaluation of the 2010 histopathological classification of anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a Bayesian network meta-analysis // Int. Urol. Nephrol. – 2018. – Vol. 50. – № 10. – P. 1853– 1861.
van Daalen E.E., Wester Trejo M.A.C., Göçeroğlu A., et al. Developments in the histopathological classification of ANCA-associated glomerulonephritis // Clin. J. Am. Soc. Nephrol. – 2020. – Vol. 15. F – № 8. – P. 1103–1111.
Aasarød K., Bostad L., Hammerstrøm J., et al. Renal histopathology and clinical course in 94 patients with Wegener’s granulomatosis // Nephrol. Dial. Transplant. – 2001. – Vol. 16. – № 5. – P.953–960.
Schnabel A., Holl-Ulrich K., Dalhoff K., et al. Efficacy of transbronchial biopsy in pulmonary vaculitides // Eur. Respir. J. – 1997. – Vol. 10. – № 12. – P.2738–2743.
Devaney K.O., Travis W.D., Hoffman G., et al. Interpretation of head and neck biopsies in Wegener’s granulomatosis. A pathologic study of 126 biopsies in 70 patients // Am. J. Surg. Pathol. – 1990. – Vol. 14. – № 6. – P.555–564.
Prasad N., Kumar S., Manjunath R., et al. Real-time ultrasound-guided percutaneous renal biopsy with needle guide by nephrologists decreases post-biopsy complications // Clin. Kidney J. – 2015. – Vol. 8. – № 2. – P.151–156.
Berden A.E., Ferrario F., Hagen E.C., et al. Histopathologic classification of ANCA- associated glomerulonephritis // J. Am. Soc. Nephrol. – 2010. – Vol. 21. – № 10. – P.1628–1636.
Brix S.R., Noriega M., Tennstedt P., et al. Development and validation of a renal risk score in ANCA-associated glomerulonephritis // Kidney Int. – 2018. – Vol. 94. – № 6. – P. 1177–1188.
Gercik O., Bilgin E., Solmaz D. Histopathological subgrouping versus renal risk score for the prediction of end-stage renal disease in ANCA-associated vasculitis // Ann. Rheu. Dis. – 2020. – Vol. 79. – № 5. – P. 675-676.
Brenner and Rector’s The Kidney / Yu A. et al. 11th Edition. – Elsevier, 2019. – P. 1192– 1277.
Moosig F., Bremer J.P., Hellmich B., et al. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg- Strauss, EGPA): Monocentric experiences in 150 patients // Ann. Rheum. Dis. – 2013. – Vol. 72. – № 6. – P.1011–1017.
Mukhtyar C., Guillevin L., Cid M.C., et al. EULAR recommendations for the management of primary small and medium vessel vasculitis // Ann. Rheum. Dis. – 2009. – Vol. 68. – № 3. – P.310–317.
Mukhtyar C., Lee R., Brown D., et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3) // Ann. Rheum. Dis. – 2009. – Vol. 68. – № 12. – P.1827– 1832.
King C., Harper L. Avoidance of Harm From Treatment for ANCA-Associated Vasculitis // Curr. Treat. Options Rheumatol. – 2017. – Vol. 3. – № 4. – P. 230–243.
Faurschou M., Sorensen I.J., Mellemkjaer L., et al. Malignancies in Wegener’s granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients // J. Rheumatol. – 2008. – Vol. 35. – № 1. – P.100–105.
Houben E., Penne E.L., Voskuyl A.E., et al. Cardiovascular events in anti-neutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis of observational studies // Rheumatology (Oxford). – 2018. – Vol. 57. – № 3. – P.555–562.
Lee J.J., Pope J.E. A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases // Arthritis Res. Ther. – 2014. – Vol. 16. – № 5. – P.435.
Moiseev S., Kronbichler A., Makarov E., et al. Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis: a multinational study // Rheumatology. – 2021. – P. keab071.
Suppiah R., Judge A., Batra R., et al. A model to predict cardiovascular events in patients with newly diagnosed Wegener’s granulomatosis and microscopic polyangiitis // Arthritis Care Res. (Hoboken). – 2011. – Vol. 63. – № 4. – P.588–596.
Макаров Е.А., Новиков П.И., Шевцова Т.П., [и др.]. Венозные тромбоэмболические осложнения при АНЦА-ассоциированных васкулитах // Клиническая фармакология и терапия. – 2017. – Т. 26. – № 3. – С.37–42.
Moiseev S., Novikov P., Bulanov N., et al. Cardiovascular risk assessment in patients with ANCA‐associated vasculitis // Arthritis Rheumatol. – 2019. [Epub ahead of print] doi:10.1002/art.41080
Кузнецова Е.И., Моисеев С.В., Новиков П.И., [и др.]. Субклинический атеросклероз периферических артерий у больных гранулематозом с полиангиитом (Вегенера) // Клиническая фармакология и терапия. – 2013. – Т. 22. – № 4. – С.36-41.
Wallace Z.S., Fu X., Liao K., et al. Disease activity, antineutrophil cytoplasmic antibody type, and lipid levels in antineutrophil cytoplasmic antibody–associated vasculitis // Arthritis Rheumatol. – 2019. – Vol. 71. – № 11. – P.1879-1887.
Walton E.W. Giant-cell granuloma of the respiratory tract (Wegener’s granulomatosis) // Br. Med. J. – 1958. – Vol. 2. – № 5091. – P.265–270.
de Groot K., Adu D., Savage C.O., et al. The value of pulse cyclophosphamide in ANCA- associated vasculitis: meta-analysis and critical review // Nephrol. Dial. Transplant. – 2001. – Vol. 16. – № 10. – P. 2018–2027.
Novack S.N., Pearson C.M. Cyclophosphamide Therapy in Wegener’s Granulomatosis // N. Engl. J. Med. – 1971. – Vol. 284. – № 17. – P.938–942.
Hoffman G.S., Kerr G.S., Leavitt R.Y., et al. Wegener Granulomatosis: An Analysis of 158 Patients // Ann. Intern. Med. – 1992. – Vol. 116. – № 6. – P.488-498.
de Groot K., Harper L., Jayne D.R., et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial // Ann. Intern. Med. – 2009. – Vol. 150. – № 10. – P.670–680.
Ntatsaki E., Carruthers D., Chakravarty K., et al. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis // Rheumatology (Oxford).. 2014. – Vol. 53. – № 12. – P.2306–2309.
Bender T.T.A., Leyens J., Sellin J., et al. Therapeutic options for patients with rare rheumatic diseases: a systematic review and meta-analysis // Orphanet J. Rare Dis. – 2020. – Vol. 15. – № 1. – P. 308.
Jones R.B., Cohen Tervaert J.W., Hauser T., et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis // N. Engl. J. Med. – 2010. – Vol. 363. – № 3. – P.211–220.
Stone J.H., Merkel P.A., Spiera R., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis // N. Engl. J. Med. – 2010. – Vol. 363. – № 3. – P.221–232.
Caroti L., Cirami C.L., Di Maria L., et al. Rituximab in relapsing and de novo MPO ANCA-associated vasculitis with severe renal involvement: A case series // BMC Nephrol. – 2019. – Vol. 20. – № 1. – P.162.
Thery-Casari C., Euvrad R., Mainbourg S., et al. Severe infections in patients with anti- neutrophil cytoplasmic antibody-associated vasculitides receiving rituximab: A meta-analysis // Autoimmun. Rev. – 2020. – Vol. 19. – № 5. – P.102505.
Jayne D.R.W., Gaskin G., Rasmussen N., et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis // J. Am. Soc. Nephrol. – 2007. – Vol. 18. – № 7. – P.2180–2188.107.
Walsh M., Merkel P.A., Peh C.-A., et al. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis // N. Engl. J. Med. – 2020. – №382. – P. 622-631.
Guillevin L., Pagnoux C., Karras A., et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis // N. Engl. J. Med. – 2014. – Vol. 371. – № 19. – P.1771–1780.109.
Yates M., Watts R.A., Bajema I.M., et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis // Ann. Rheum. Dis. – 2016. – Vol. 75. – № 9. – P. 1583–1594.
Chanouzas D., McGregor J.A.G., Nightingale P., et al. Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: A multi- center retrospective cohort study 11 Medical and Health Sciences 1103 Clinical Sciences // BMC Nephrol. – 2019. – Vol. 20. – № 1. – P.58.
Xiong A., Xiong C., Yang G., et al. The Role of Mycophenolate Mofetil for the Induction of Remission in ANCA-Associated Vasculitis: A Meta-Analysis // Front. Med. – 2021. – Vol. 8. – P. 609924.
Kuzuya K., Morita T., Kumanogoh A. Efficacy of mycophenolate mofetil as a remission induction therapy in antineutrophil cytoplasmic antibody: Associated vasculitis - A meta- analysis // RMD Open. – 2020. Vol. 6. – № 1. – P. e001195.
Hu W., Liu C., Xie H., et al. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement // Nephrol. Dial. Transplant. – 2008. – Vol. 23. – № 4. – P.1307–1312.
Han F, Liu G, Zhang X, et al. Effects of mycophenolate mofetil combined with corticosteroids for induction therapy of microscopic polyangiitis // Am. J. Nephrol. – 2011. – Vol. 33. – № 2. – P.185–192.
Tuin J., Stassen P.M., Bogdan D.I., et al. Mycophenolate mofetil versus cyclophosphamide for the induction of remission in nonlife-threatening relapses of antineutrophil cytoplasmic antibody–associated vasculitis // Clin. J. Am. Soc. Nephrol. – 2019. – Vol. 14. – № 7. – P.1021–1028.
Jones R.B., Hiemstra T.F., Ballarin J., et al. Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: A randomised, non- inferiority trial // Ann. Rheum. Dis. – 2019. – Vol. 78. – № 3. – P.399-405.117.
Szpirt W.M., Heaf J.G., Petersen J. Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener’s granulomatosisa clinical randomized controlled trial // Nephrol. Dial. Transplant. – 2011. – Vol. 26. – № 1. – P.206–213.
Pusey C.D., Rees A.J., Evans D.J., et al. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies // Kidney Int. – 1991. – Vol. 40. – № 4. – P.757–763.
Yamada Y., Harada M., Hara Y., et al. Efficacy of plasma exchange for antineutrophil cytoplasmic antibody-associated systemic vasculitis: a systematic review and meta-analysis // Arthritis Res. Ther. – 2021. – Vol. 23. – № 1. – P. 28.
Levy J.B., Hammad T., Coulthart A., et al. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies // Kidney Int. – 2004. – Vol. 66. – № 4. – P.1535–1540.
Puéchal X., Pagnoux C., Baron G., et al. Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (churg-strauss), microscopic polyangiitis, or polyarteritis nodosa without poor prognosis factors: a randomized, controlled trial // Arthritis Rheumatol. – 2017. – Vol. 69. – № 11. – P.2175–2186.
Метотрексат - инструкция по применению. Государственный реестр лекарственных средств. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=ae81c79d-317b-45ce- 8a6e-8da5456e9164&t=
Lionaki S., Hogan S.L., Jennette C.E., et al. The clinical course of ANCA small-vessel vasculitis on chronic dialysis // Kidney Int. – 2009. – Vol. 76. – № 6. – P.644–651.124.
Geetha D., Jefferson J.A. ANCA-Associated Vasculitis: Core Curriculum 2020 // Am. J. Kidney Dis. – 2019. – P. 1–14.
Charles P., Terrier B., Perrodeau E., et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: Results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2) // Ann. Rheum. Dis. – 2018. – Vol. 77. – № 8. – P.1144–1150.
Smith R.M., Jones R.B., Specks U., et al. Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis // Ann. Rheum. Dis. – 2020. – Vol. 79. – № 9. – P. 1243– 1249.
Pagnoux C., Mahr A., Hamidou M.A., et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis // N. Engl. J. Med. – 2008. – Vol. 359. – P. 2790–2803.
Hiemstra T.F., Walsh M., Mahr A., et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial // JAMA. – 2010. – Vol. 304. – № 21. – P.2381–2388.
He P., Hu J.-P., Tian X.-J., et al. Prevalence and risk factors of relapse in patients with ANCA-associated vasculitis receiving cyclophosphamide induction: a systematic review and meta-analysis of large observational studies // Rheumatology. – 2021. – Vol. 60. – № 3. – P. 1067–1079.
Langford C.A., Talar-Williams C., Barron K.S., et al. Use of a cyclophosphamide- induction methotrexate-maintenance regimen for the treatment of Wegener’s granulomatosis: Extended follow-up and rate of relapse // Am. J. Med. – 2003. – Vol. 114. – № 6. – P.463–469.
Reinhold-Keller E., Fink C.O., Herlyn K., et al. High rate of renal relapse in 71 patients with Wegener’s granulomatosis under maintenance of remission with low-dose methotrexate // Arthritis Rheum. – 2002. – Vol. 47. – № 3. – P.326–332.
Weidanz F., Day C.J., Hewins P., et al. Recurrences and infections during continuous immunosuppressive therapy after beginning dialysis in ANCA-associated vasculitis // Am. J. Kidney Dis. – 2007. – Vol. 50. – № 1. – P.36–46.
Chen M., Zhao M.H. Severe pulmonary hemorrhage in patients with end-stage renal disease in antineutrophil cytoplasmic autoantibody-associated vasculitis // Am. J. Med. Sci. – 2009. – Vol. 337. – № 6. – P.411–414.
Springer J., Nutter B., Langford C.A. et al. Granulomatosis with polyangiitis (Wegener’s): Impact of maintenance therapy duration // Medicine (Baltimore). – 2014. – Vol. 93. – № 2. – P.82–90.
Karras A., Pagnoux C., Haubitz M., et al. Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis // Ann. Rheum. Dis. – 2017. – Vol. 76. – № 10. – P.1662–1668.
Charles P., Perrodeau E., Samson M., et al. Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Trial // Ann. Intern. Med. – 2020. – Vol. 173. – № 3. – P. 179–187.
Walsh M., Merkel P.A., Mahr A., et al. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis // Arthritis Care Res. – 2010. – Vol. 62. – № 8. – P.1166–1173.
Pagnoux C., Quemeneur T., Ninet J., et al. Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: Results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy // Arthritis Rheumatol. – 2015. – Vol. 67. – № 4. – P.1117–1127
Hellmich B., Flossman O., Gross W.L., et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis // Ann. Rheum. Dis. – 2007. – Vol. 66. – № 5. – P.605–617.
Cartin-Ceba R., Keogh K.A., Specks U., et al. Rituximab for the treatment of Churg- Strauss syndrome with renal involvement // Nephrol. Dial. Transplant. – 2011. – Vol. 26. – № 9. – P.2865–2871.
Pullerits R., Ljevak M., Vikgren J., et al. Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: long-term follow-up from a single centre // Scand. J. Immunol. – 2012. – Vol. 76. – № 4. – P.411–420.
Miloslavsky E.M., Specks U., Merkel P.A., et al. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis // Arthritis Rheum. – 2013. – Vol. 65. – № 9. – P.2441–2449.
Shimizu T., Morita T., Kumanogoh A. The therapeutic efficacy of intravenous immunoglobulin in anti-neutrophilic cytoplasmic antibody-associated vasculitis: A meta-analysis // Rheumatology (United Kingdom). Oxford University Press, 2020. Vol. 59, № 5. P. 959–967.
Fortin P.M., Tejani A.M., Bassett K., et al. Intravenous immunoglobulin as adjuvant therapy for Wegener’s granulomatosis // Cochrane Database of Syst. Rev. – 2013. – Vol. 3. – P.CD0070057.
Muso E., Ito-Ihara T., Ono T., et al. Intravenous immunoglobulin (IVIg) therapy in MPO- ANCA related polyangiitis with rapidly progressive glomerulonephritis in Japan // Jpn. J. Infect. Dis. – 2004. – Vol. 57. – № 5. – P.S17-8.
Jayne D.R., Chapel H., Adu D., et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity // Q.J.M. – 2000. – Vol. 93. – № 7. – P.433– 439.
Tang W., Bose B., McDonald S.P., et al. The outcomes of patients with ESRD and ANCA-associated Vasculitis in Australia and New Zealand // Clin. J. Am. Soc. Nephrol. – 2013. – Vol. 8. – № 5. – P.773–780.
Hruskova Z., Stel V.S., Jayne D., et al. Characteristics and outcomes of granulomatosis with polyangiitis (Wegener) and microscopic polyangiitis requiring renal replacement therapy: Results from the European renal association-european dialysis and transplant association registry // Am. J. Kidney Dis. – 2015. – Vol. 66. – № 4. – P.613–620.
O’Shaughnessy M.M., Liu S., Montez-Rath M.E., et al. Kidney transplantation outcomes across GN subtypes in the United States // J. Am. Soc. Nephrol. – 2017. – Vol. 28. – № 2. – P.632–644.
Geetha D., Eirin A., True K., et al. Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis: A multicenter experience // Transplantation. – 2011. – Vol. 91. – № 12. – P.1370–1375.
Little M.A., Hassan B., Jackues S., et al. Renal transplantation in systemic vasculitis: When is it safe? // Nephrol. Dial. Transplant. – 2009. – Vol. 24. – № 10. – P.3219–3225.
Marco H., Mirapeix E., Arcos E., et al. Long-term outcome of antineutrophil cytoplasmic antibody-associated small vessel vasculitis after renal transplantation // Clin. Transplant. – 2013. – Vol. 27. – № 3. – P.338–347.
Stern A., Green H., Paul M., et al. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients // Cochrane database Syst. Rev. – 2014. – № 10. – P.CD005590.
Kronbichler A., Keschbaum J., Gopaluni S., et al. Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis // Ann. Rheum. Dis. – 2018. – Vol. 77. – № 10. – P. 1440-1147.
Mahr A., Girard T., Agher R., et al. Analysis of factors predictive of survival based on 49 patients with systemic Wegener’s granulomatosis and prospective follow-up // Rheumatology (Oxford). – 2001. – Vol. 40. – № 5. – P.492–498.
Bligny D., Nahr A., Toumelin P.L., et al. Predicting mortality in systemic Wegener’s granulomatosis: A survival analysis based on 93 patients // Arthritis Rheum. – 2004. – Vol. 51. – № 1. – P.83–91.
Kronbichler A., Jayne D.R.W., Mayer G. Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis // European Journal of Clinical Investigation. – 2015. – Vol. 45. – № 3. – P.346–368.
Furer V., Rondaan C., Heijstek M.W., et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases // Ann. Rheum. Dis. – 2020. – Vol. 79. – № 1. P. 39–52.
Groh M., Puechal X., Terrier B., et al. Failure of pneumococcal immunization during remission induction treatment of ANCA-associated vasculitis: The Pneumovas Pilot 1 study // Joint Bone Spine. – 2017. – Vol. 84. – № 5. – P.643–644.
Stassen P.M., Sanders J.S., Kallenberg C.G.M., et al. Influenza vaccination does not result in an increase in relapses in patients with ANCA-associated vasculitis // Nephrol. Dial. Transplant. – 2008. – Vol. 23. – № 2. – P.654–658.
Jeffs L.S., Peh C.A., Jose M.D., et al. Randomized trial investigating the safety and efficacy of influenza vaccination in patients with antineutrophil cytoplasmic antibody -associated vasculitis // Nephrology. – 2015. – Vol. 20. – № 5. – P.343–351.
Reinhold-Keller E., Beuge N., Latza U., et al. An interdisciplinary approach to the care of patients with Wegener’s granulomatosis: long-term outcome in 155 patients // Arthritis Rheum. – 2000. – Vol. 43. – № 5. – P. 1021-1032.
Homik J., Suarez-Almazor M.E., Shea B., et al. Calcium and vitamin D for corticosteroid-induced osteoporosis // Cochrane Database Syst. Rev. – 2000. – Vol. 1998. – № 2. - CD000952.
Allen C.S., Yeung J.H., Vandermeer B., et al. Bisphosphonates for steroid-induced osteoporosis // Cochrane Database of Syst. Rev. – 2016. – Vol. 2016. – № 10. – P. CD001347.
Fredi M., Lazzaroni M.G., Tani C., et al. Systemic vasculitis and pregnancy: A multicenter study on maternal and neonatal outcome of 65 prospectively followed pregnancies // Autoimmun. Rev. – 2015. – Vol. 14. – № 8. – P. 686–691.
Veltri N.L., Hladunewich M., Bhasin A., et al. De novo antineutrophil cytoplasmic antibody-associated vasculitis in pregnancy: a systematic review on maternal, pregnancy and fetal outcomes // Clin. Kidney J. – 2018. – Vol. 11. – № 5. – P. 659–666.
Leroy C., Rigor J.-M., Leroy M., et al. Immunosuppressive drugs and fertility // Orphanet J. Rare Dis. – 2015. – Vol. 10. – 136.
Langford C.A. Update on Wegener granulomatosis // Cleve. Clin. J. Med. – 2005. – Vol. 72. – № 8. – P.689–697.
Seo P., Min Y.I., Holbrook J.T., et al. Damage caused by Wegener’s granulomatosis and its treatment: prospective data from the Wegener’s Granulomatosis Etanercept Trial (WGET) // Arthritis Rheum. – 2005. – Vol. 52. – № 7. – P.2168–2178.
Flossmann O., Berden A., de Groot K., et al. Long-term patient survival in ANCA- associated vasculitis // Ann. Rheum. Dis. – 2011. – Vol. 70. – № 3. – P.488–494.
Basu N., McClean A., Harper L., et al. Explaining fatigue in ANCA-associated vasculitis // Rheumatology (Oxford). – 2013. – Vol. 52. – № 9. – P.1680–1685.
O’Malley L., Druce K., Chanouzas D., et al. The longitudinal course of fatigue in ANCA associated vasculitis // J. Rheumatol. – 2019. – P. jrheum.190113. doi: 10.3899/jrheum.190113.
Basu N., McClean A., Harper Let al. Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis // Rheumatology (Oxford). – 2014. – Vol. 53. – № 5. – P.953–956.
Yun J.D., Ha J., Kim S., et al. Predictor of depressive disorders in patients with antineutrophil cytoplasmic antibody-associated vasculitis // Clin. Rheumatol. – 2019. – Vol. 38. – № 12. – P.3485-3491.
Basu N., McClean A., Harper L., et al. The characterisation and determinants of quality of life in ANCA associated vasculitis // Ann. Rheum. Dis. – 2014. – Vol. 73. – № 1. – P.207– 211.
Herlyn K., Gross W.L., Reinhold-Keller E. Longitudinale effekte des strukturierten patientenschulungsprogramms für vaskulitispatienten // Z. Rheumatol. – 2008. – Vol. 67. – № 3. – P. 206–210.
Hauer H.A., Bajema I.M., van Houwelingen H.C., et al. Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients // Kidney Int. – 2002. – Vol. 62. – № 5. – P.1732–1742.
de Lind van Wijngaarden R.A., Hauer H.A., Wolterbeek R., et al. Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement // J. Am. Soc. Nephrol. – 2006. – Vol. 17. – № 8. – P.2264–2274.
Hogan S.L., Nachman P.H., Wilkman A.S., et al. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis // J. Am. Soc. Nephrol. – 1996. – Vol. 7. – № 1. – P.23–32.
Pagnoux C., Hogan S.L., Chin H., et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts // Arthritis Rheum. – 2008. – Vol. 58. – № 9. – P.2908–2918.
Lionaki S., Blyth E.R., Hogan S.L., et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis // Arthritis Rheum. – 2012. – Vol. 64. – № 10. – P.3452–3462
Holle J.U., Gross W.L., Latza U., et al. Improved outcome in 445 patients with Wegener’s granulomatosis in a German vasculitis center over four decades // Arthritis Rheum. – 2011. – Vol. 63. – № 1. – P.257–266.
Mukhtyar C., Flossman O., Hellmich B., et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force // Ann. Rheum. Dis. – 2008. – Vol. 67. – № 7. – P.1004–1010.
Flossmann O., Berden A., de Groot K., et al. Long-term patient survival in ANCA- associated vasculitis // Ann. Rheum. Dis. – 2011. – Vol. 70. – № 3. – P.488–494.
Семенкова Е.Н., Кривошеев О.Г., Новиков П.И. Поражение легких при гранулематозе Вегенера // Клиническая медицина. – 2011. – T. 1. – C.10–13.